Portal de investigación
Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Perl, AE
- Martinelli, G
- Cortes, JE
- Neubauer, A
- Berman, E
- Paolini, S
- Baer, MR
- Larson, RA
- Ustun, C
- Fabbiano, F
- Di Stasi, A
- Stuart, R
- Olin, R
- Kasner, M
- Ciceri, F
- Chou, WC
- Podoltsev, N
- Recher, C
- Yokoyama, H
- Hosono, N
- Yoon, SS
- Lee, JH
- Pardee, T
- Fathi, AT
- Liu, CF
- Liu, X
- Bahceci, E
- Levis, MJ
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0008-5472, 1538-7445
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 4,051 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CANCER RESEARCH AMER ASSOC CANCER RESEARCH
Citas Recibidas en Web of Science: 30
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Perl,AE,Martinelli,G,Cortes,JE,Neubauer,A,Berman,E,Paolini,S,Montesinos,P et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. Annual Meeting of the American-Association-for-Cancer-Research (AACR). 2019. Atlanta. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404:AMER ASSOC CANCER RESEARCH. 2019.